Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

1. MVA85A vaccine to enhance BCG for preventing tuberculosis. (PubMed)

MVA85A vaccine to enhance BCG for preventing tuberculosis. Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vaccine produced to prevent tuberculosis.To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.We searched the Cochrane Infectious Diseases Group (...) Specialized Register; Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (Ovid); and four other databases. We searched the WHO ICTRP and ClinicalTrials.gov. All searches were run up to 10 May 2018.We evaluated randomized controlled trials of MVA85A vaccine given with BCG in people regardless of age or HIV status.Two review authors independently assessed the eligibility and risk of bias of trials, and extracted and analyzed data. The primary outcome was active tuberculosis disease

Full Text available with Trip Pro

2019 Cochrane

2. Tuberculosis. (PubMed)

Tuberculosis. Tuberculosis remains the leading cause of death from an infectious disease among adults worldwide, with more than 10 million people becoming newly sick from tuberculosis each year. Advances in diagnosis, including the use of rapid molecular testing and whole-genome sequencing in both sputum and non-sputum samples, could change this situation. Although little has changed in the treatment of drug-susceptible tuberculosis, data on increased efficacy with new and repurposed drugs have (...) led WHO to recommend all-oral therapy for drug-resistant tuberculosis for the first time ever in 2018. Studies have shown that shorter latent tuberculosis prevention regimens containing rifampicin or rifapentine are as effective as longer, isoniazid-based regimens, and there is a promising vaccine candidate to prevent the progression of infection to the disease. But new tools alone are not sufficient. Advances must be made in providing high-quality, people-centred care for tuberculosis. Renewed

2019 Lancet

3. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. (PubMed)

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates.We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9 (...) -month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25.A total of 3000 patients were enrolled and followed for a median

2019 NEJM

4. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. (PubMed)

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. Cohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011.We conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides. Participants were randomly assigned, in a 2:1 (...) ratio, to receive a short regimen (9 to 11 months) that included high-dose moxifloxacin or a long regimen (20 months) that followed the 2011 WHO guidelines. The primary efficacy outcome was a favorable status at 132 weeks, defined by cultures negative for Mycobacterium tuberculosis at 132 weeks and at a previous occasion, with no intervening positive culture or previous unfavorable outcome. An upper 95% confidence limit for the between-group difference in favorable status that was 10 percentage

2019 NEJM

5. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. (PubMed)

Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Directly observed treatment (DOT) has been the standard of care for tuberculosis since the early 1990s, but it is inconvenient for patients and service providers. Video-observed therapy (VOT) has been conditionally recommended by WHO as an alternative to DOT. We tested whether levels of treatment observation were improved with VOT.We (...) did a multicentre, analyst-blinded, randomised controlled superiority trial in 22 clinics in England (UK). Eligible participants were patients aged at least 16 years with active pulmonary or non-pulmonary tuberculosis who were eligible for DOT according to local guidance. Exclusion criteria included patients who did not have access to charging a smartphone. We randomly assigned participants to either VOT (daily remote observation using a smartphone app) or DOT (observations done three to five

Full Text available with Trip Pro

2019 Lancet

6. Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region

Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region Real-world epidemiological data on the risk of tuberculosis (TB) in patients with immune-mediated diseases treated with biologics are scarce in TB endemic areas. We investigated the incidence of TB in a population-based setting and stratified the risk of TB among different biological therapies.We collected medical data from a territory-wide

2019 EvidenceUpdates

7. Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study

Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study A single center pilot study, open labeled, prospective randomized clinical trial.To compare six versus 12 months of anti TB therapy in patients with biopsy proven spinal TB.There is no clear consensus or evidence based guidelines for the duration of treatment of spinal tuberculosis. We studied if 6 and 12 months (...) of anti tubercular therapy (ATT) had equivalent outcomes at 24 months from completion of therapy.A prospective randomized open labeled clinical trial of 6 versus 12 months ATT in patients with biopsy proven spinal-vertebral tuberculosis. The primary end point was absence of recurrence 24 months after completing therapy. Secondary end points were clinical cure at the end of therapy, significant adverse effect of ATT, need for delayed surgery, and residual neurological dysfunction.Hundred patients

2019 EvidenceUpdates

8. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study

Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy.In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly

2019 EvidenceUpdates

9. Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review

Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review The global loss to follow-up (LTFU) rate among drug-resistant tuberculosis (DR-TB) patients remains high at 15%. We conducted a systematic review to explore interventions to reduce LTFU during DR-TB treatment.We searched for studies published between January 2000 and December 2017 that provided any form of psychosocial or material support for patients with DR

2019 EvidenceUpdates

10. Programmatic management of latent tuberculosis infection in the European Union

Programmatic management of latent tuberculosis infection in the European Union SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union www.ecdc.europa.euECDC SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union ii This guidance was commissioned by ECDC and coordinated by Senia Rosales Klintz, Netta Beer and Marieke J. van der Werf with the support of Helena de Carvalho Gomes (ECDC). The inventory of expert (...) Kingdom), and its members: Judith Bruchfeld (Sweden); Josie Garrett (United Kingdom); Walter Haas (Germany); Einar Heldal (Norway); Rein Houben (United Kingdom); Philip LoBue (USA); Mike Mandelbaum (United Kingdom); Alberto Matteelli (Italy); Giovanni Battista Migliori (Italy); Ivan Solovic (Slovakia); and Martina Vašáková (Czech Republic). Suggested citation: European Centre for Disease Prevention and Control. Programmatic management of latent tuberculosis infection in the European Union. Stockholm

2019 European Centre for Disease Prevention and Control - Public Health Guidance

11. Approaches to detecting tuberculosis in children and youth

Approaches to detecting tuberculosis in children and youth This practice point provides a framework for initiating investigation in children suspected of having infection with  Mycobacterium tuberculosis  (Mtb). Some areas in Canada have a high burden of tubercular disease, with Indigenous populations being most at risk. Tuberculosis (TB) can present either as an acute or subacute illness and both primary or reactivation infection can cause pulmonary or multisystem disease (...) . Tuberculin skin tests and interferon-γ release assays can be used to support a suspected diagnosis. TB elimination in Canada is possible but requires improving social determinants of health, one of the major factors contributing to the spread of TB in populations at risk. Keywords: Bacille-Calmette-Guérin; Break of contact; Latent tuberculosis infection; Mycobacterium tuberculosis; Tuberculosis  

2019 Canadian Paediatric Society

12. Epidemiology of venous thrombosis in people with tuberculosis: a systematic review and meta-analysis protocol

Epidemiology of venous thrombosis in people with tuberculosis: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

13. Operationalization of malnutrition as assessed in adult patients with tuberculosis: a systematic review

Operationalization of malnutrition as assessed in adult patients with tuberculosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

14. Interferon gamma-induced protein 10 (IP-100 for the diagnosis of tuberculosis in children

Interferon gamma-induced protein 10 (IP-100 for the diagnosis of tuberculosis in children Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

15. Effective pharmaceutical care on tuberculosis treatment outcomes: a systematic review of randomised and observational studies

Effective pharmaceutical care on tuberculosis treatment outcomes: a systematic review of randomised and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

16. Systematic review of association between silica/silicosis and tuberculosis

Systematic review of association between silica/silicosis and tuberculosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

17. A systematic review and meta-analysis of the effect of HIV status on the incidence of tuberculosis disease among individuals with latent Mycobacterium tuberculosis infection

A systematic review and meta-analysis of the effect of HIV status on the incidence of tuberculosis disease among individuals with latent Mycobacterium tuberculosis infection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

18. The global prevalence of latent tuberculosis: a systematic review and meta-analysis

The global prevalence of latent tuberculosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

19. The role of IP-10 in tuberculosis treatment monitoring: a systematic review

The role of IP-10 in tuberculosis treatment monitoring: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

20. Risk of depression in pulmonary tuberculosis

Risk of depression in pulmonary tuberculosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO